pharma news today glp-1 obesity drug What is the pipeline for future medications for obesity? Consumer group presses U.S. to
Description
Three reports to date suggest that VTA and NAc GLP-1Rs induced suppression of food intake and reward is not associated with visceral illness (Dossat et al., 2011
10 Blocking the reward value of food may expose latent behavioral vulnerabilities in high-risk patients
2013;16(3):e97
Contrave is an oral medication combining bupropion and naltrexone to target appetite and cravings in the brain
The key principle is to reduce slowly and monitor continuously, treating any upward weight trend as a signal to pause the reduction or increase one step
